The briefing
ResoTher Pharma reported that heart attack drug RTP-026 was well tolerated and showed early efficacy signals in a 66-patient Phase 2a study. The results fulfill a key condition for Swedish-listed Hunter Capital RTO 1’s planned reverse acquisition of the company.
Original headline
ResoTher heart data clear acquisition hurdle, set up 200